Association of apolipoprotein E polymorphisms and dietary factors in colorectal cancer by Mrkonjic, M et al.
Association of apolipoprotein E polymorphisms and dietary











2,4,6 and B Bapat*,1,2,3
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada M5G 1L5;
2Samuel Lunenfeld Research Institute,
Mount Sinai Hospital, Toronto, ON, Canada M5T 3L9;
3Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
M5G 1X5;
4Prosserman Centre for Health Research, Mount Sinai Hospital, Toronto, ON, Canada M5T 3L9;
5Ontario Familial Colorectal Cancer Registry,
Cancer Care Ontario, Toronto, ON, Canada M5G 3L7;
6Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada M5T 3M7;
7Department of Surgery, Mount Sinai Hospital, Toronto, ON, Canada M5G 1X5;
8Department of Surgery, University of Toronto, Toronto, ON, Canada
M5G 1L5;
9Ottawa Health Research Institute, Ottawa, ON, Canada K1Y 4E9
ApoE single nucleotide polymorphisms (SNPs) Cys112Arg (Epsilon-4), and Arg158Cys (Epsilon-2) have been implicated in
cardiovascular and Alzheimer’s disease, but their role in colorectal cancer (CRC) has not been extensively studied. We investigated
whether ApoE polymorphisms alone or in combination with dietary factors selectively contribute to mismatch-repair (MMR)
proficient (microsatellite stable/low or MSS/L) vs deficient (microsatellite unstable or MSI-H) CRCs. We carried out a case–control
study with 906 CRC cases and 911 unaffected controls to examine the associations between ApoE polymorphisms and dietary
factors and assessed their contribution to MSS/L and MSI-H CRCs. We used unconditional logistic regression to evaluate the
associations between ApoE SNPs, tumour MSI status, and dietary factors after adjusting for age and sex. All statistical tests were two-
sided. No significant differences in ApoE genotype frequencies were observed between CRC cases and unaffected controls. We
observed that increased dietary intake of total fat, saturated fat, cholesterol, and red meat was significantly associated with CRC.
Among non-ApoE4 carriers, 2–4 and 44 red meat servings/week were associated with developing MSS/L CRC (OR¼1.51, 95% CI
1.10–2.07 and OR¼1.80, 95% CI 1.30–2.48, respectively), whereas among ApoE4 allele carriers, four or more red meat servings/
week were associated with MSI-H CRC (OR¼4.62, 95% CI 1.20–17.77) when compared with the controls. ApoE isoforms
modulate the risk of MSI-H and MSS/L CRCs among high red meat consumers.
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Colorectal cancer (CRC) is a common malignancy and the second
leading cause of cancer-related deaths in North America (Jemal
et al, 2007). On the basis of mismatch-repair (MMR) functional
status, CRCs can be subdivided into MMR-deficient, microsatellite
unstable (MSI-H) and MMR-proficient, microsatellite stable (MSS)
tumours. In addition to genetic alterations in tumour suppressor
genes and oncogenes that are responsible for MSS tumours or
defects in the DNA mismatch repair (Lynch and de la Chapelle,
2003), mutations and single nucleotide polymorphisms in genes
involved in the metabolic pathways have also been implicated in
CRC but to a lesser extent. Diets high in red and processed meat
have been shown to increase risk of CRC, whereas diets rich in
fruits, vegetables, and fibre lower CRC risk (Emmons et al, 2005;
Ferrari et al, 2007). As dietary animal fat is a risk factor for CRC
(Bautista et al, 1997; Slattery et al, 2000; Diergaarde et al, 2003;
Wark et al, 2006), genetic alterations involved in the regulation of
lipid transport and metabolism are potential susceptibility factors
for colon cancer.
ApoE plays a multi-functional role in lipoprotein metabolism by
acting as a high-affinity ligand for receptors of the LDL receptor
family and serving as a cofactor in VLDL synthesis, as well as the
hydrolysis of VLDL remnants in LDL production (Minihane et al,
2007). However, recent studies have identified ApoE functions
other than lipid metabolism such as DNA synthesis, b-catenin
localisation, cell proliferation, antioxidant abilities, angiogenesis,
and metastasis that may play a role in CRC (Vogel et al, 1994;
Grocott et al, 2001; Niemi et al, 2002; Cedazo-Minguez et al, 2003).
The most widely studied polymorphisms in ApoE gene are
Cys112Arg (rs429358) and Arg158Cys (rs7412), which create
three distinct protein isoforms: ApoE2-epsilon2 (112Cys/158Cys),
wild-type ApoE3-epsilon3 (112Cys/158Arg), and ApoE4-epsilon4
(112Arg/158Arg) (Weisgraber et al, 1981; Rall et al, 1982). ApoE4
is considered the high-risk isoform for chronic heart disease,
Alzheimer’s disease, and age-related cognitive decline (Corder
et al, 1993; Wilson et al, 1996; Bretsky et al, 2003). However, the
role of ApoE isoforms in CRC is not well established. All ApoE
allelic variants are associated with distinct patterns of lipid
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stransport and metabolism, and are shown to modulate entero-
hepatic metabolism of cholesterol and bile acids, which are
implicated in promoting colorectal tumorigenesis (Debruyne et al,
2002; Minihane et al, 2007). Consequently, ApoE alleles are
candidate risk factors for CRC. In a small study, ApoE4 was found
to be protective from developing adenomas and carcinomas of the
proximal colon (Kervinen et al, 1996), where the MSI-H subset of
CRCs usually develop. A similar, but weak, inverse correlation of
ApoE4 with proximal colonic location was reported among
Australian CRC patients (Butler et al, 2001). MSI-H CRCs have
distinct clinical and pathological manifestations from MSS CRCs
such as: proximal colon location, mucinous histology, poor
differentiation, Crohn-like reaction, tumour infiltrating lympho-
cytes (Alexander et al, 2001), and drug response (Elsaleh et al,
2001), and it is likely that distinct genetic and/or dietary risk
factors contribute to these distinct CRC features. However, no
study has evaluated the role of ApoE isoforms in CRC subtypes
recognised by mismatch-repair deficient (MSI-H) and proficient
(none or low microsatellite instability, MSS/L) profiles.
In this study, we investigated whether ApoE gene polymor-
phisms are associated with MSI-H and MSS/L CRC and whether
they interact with dietary factors.
MATERIALS AND METHODS
Study subjects
The accrual of CRC patients and unaffected controls, the response
rates, population characteristics, and ethnic backgrounds were
described earlier (Mrkonjic et al, 2007; Raptis et al, 2007). Briefly,
CRC cases and unaffected controls from the province of Ontario
were obtained from the Ontario Familial Colorectal Cancer
Registry (OFCCR). A total of 906 cases, aged 20–74 years, and
diagnosed during the years 1997–2000, were identified for this
study along with 911 unaffected controls. Ninety-five percent of
participants in the OFCCR are of Caucasian ethnicity. Family
history was collected by mailed questionnaires and was then used
to construct pedigrees. Patients were classified by family risk.
Further risk factor information was collected from two other
mailed questionnaires and blood and tissue specimens were
obtained. CRC patients were also stratified by family risk as
described earlier by Cotterchio et al (2000). No apparent cases
with familial adenomatous polyposis coli were included in the
case series.
In addition to personal and family risk questionnaires,
participants were also asked to complete a Food Frequency
Questionnaire (FFQ). The FFQ was developed by the Epidemiology
Program, Cancer Research Center of Hawaii and has been
described earlier and validated (Cotterchio et al, 2008). Food
frequency questionnaires were analysed using food composition
databases that include values for macro- and micronutrients
(Cotterchio et al, 2008). Data on saturated fat (grams), total fat
(grams), and total cholesterol (milligrams), folacin (milligrams),
and alcoholic beverages (per week) was obtained from the FFQ and
was placed into quartiles. The frequency of red meat intake
(servings per week) was obtained from a separate risk factor
questionnaire and the values were also placed into quartiles. The
research ethics boards of Mount Sinai Hospital and the University
of Toronto approved all protocols.
Molecular genetic analysis
Single nucleotide polymorphism genotyping Genomic DNA was
extracted from peripheral blood lymphocytes using phenol–
chloroform or the Qiagen DNA extraction kit (Qiagen Inc.,
Montgomery County, MD, USA) as reported earlier (Mrkonjic
et al, 2007; Raptis et al, 2007). Restriction Fragment Length
Polymorphism (RFLP) was used to initially genotype the ApoE
polymorphisms in CRC cases as described earlier (Gioia et al,
1998). Briefly, the initial PCR yields an amplicon of 485bp of ApoE
exon 4 containing both polymorphisms. The secondary, nested
PCR yields a 300bp product. The conditions of both PCRs, primer
sequences, and restriction digestion analysis have been described
earlier (Gioia et al, 1998). HhaI digestion of the nested amplicon
generated unique patterns of restriction fragments depending on
the original genotype of the individual. ApoE2 and ApoE3 lack
HhaI restriction site at codon 112 and ApoE2 lacks the HhaI
restriction site at codon 158. The restriction fragments were
visualised through electrophoresis on a 4% agarose gel (Invitrogen,
Burlington, Ontario, Canada).
With the availability of SNP genotyping arrays, we have
genotyped CRC cases and unaffected controls for the ApoE4 SNP
(rs429358) using the Illumina Golden Gate Assay (Illumina Inc.,
San Diego, CA, USA) as described earlier (Zanke et al, 2007). We
used our previous RFLP genotyping of CRC cases for the rs429358
SNP to validate the genotyping calls. Because the ApoE2 SNP
(rs7412) was not successfully genotyped using the Illumina Golden
Gate Assay, we used TaqMan allelic discrimination assay to
genotype the unaffected controls. The sequences of primers and
probes are: forward primer CGCGATGCCGATGACCT, reverse
primer GGCCCCGGCCTGGTAC, wild-type probe 6FAM-ACTGC
CAGGCGCTTC-MGBNFQ, and variant probe VIC-ACTGCCAGG
CACTTC-MGBNFQ. The conditions for the allelic discrimination
reaction have been described earlier (Mrkonjic et al, 2007).
Additional independent validation for ApoE3/E4 was done on
55% of samples by TaqMan allelic discrimination assay as
described earlier (MacLeod et al, 2001). The PCR conditions
and primer/probe sequences have also been described earlier
(MacLeod et al, 2001). All assays were run in 96-well poly-
propylene plates (Axygen Scientific, Union City, CA, USA) and the
results were analysed using the Applied Biosystems 7900HT
Sequence Detection system and accompanying software, SDS
version 2.0 and/or 2.1 (Applied Biosystems, Foster City, CA, USA).
Tumour microsatellite instability (MSI) analysis MSI analysis was
performed as described earlier (Raptis et al, 2007). Briefly, paraffin-
embedded colorectal tumour tissue of incident cases, and normal
tissue from the same patient, were microdissected in areas with
470% cellularity in tumour and normal cell populations,
respectively. MSI analysis was carried out using five or more
microsatellite markers from the NCI recommended panel of 10
microsatellite markers; these markers consist of mononucleotides
BAT-25, BAT-26, BAT-40, and BAT-34C4, dinucleotides D2S123,
D5S346, ACTC, D18S55, and D10S197, and one penta-mono-tetra
compound marker, MYC-L (Boland et al, 1998). The presence of
altered/additional bands that resulted from the tumour PCR-
amplified product, when compared with the matched normal colon
PCR product, indicated MSI. Tumours were classified as MSI high
(MSI-H, X30% unstable markers among all markers tested), MSI
low (MSI-L, o30% markers unstable) or microsatellite stable (MSS,
no unstable markers) as per NCI recommended guidelines for MSI
testing (Boland et al, 1998). MSI-L and MSS groups were combined
into one group, hereafter referred to as simply ‘MSS/L’, for analysis
purposes. Primer sequences and PCR amplification conditions for
MSI testing have been described earlier (Raptis et al, 2007).
Statistical analysis
The associations of ApoE2 and ApoE4 with colorectal cancer
incidence, and with colorectal cancer subsets (MSI-H and MSS/L)
were evaluated with a two-sided Pearson’s w
2 test, in which a
P-value of less than 0.05 was considered statistically significant.
Unconditional logistic regression was also used to evaluate the
association between ApoE2 and ApoE4 and CRC and its subsets,
after adjusting for age and sex. The dietary differences between
all CRC cases, or subsets stratified by tumour MSI status, and
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sunaffected controls were evaluated using Pearson’s w
2 or Fisher’s
exact test and with unconditional logistic regression, after
adjusting for age and sex. Dietary differences between CRC subsets
(MSI-H, MSS/L) and unaffected controls were also examined by
ApoE4 and ApoE2 carrier status using unconditional logistic
regression. In addition, we also examined differences in tumour
location, stage and grade between MSI-H and MSS/L CRCs using
Pearson’s w
2 test and unconditional logistic regression. Chi-square
and Fisher’s exact tests, and logistic regression were performed
with SAS version 9.0 (SAS Institute, Cary, NC, USA). All statistical
tests were two-sided with a P-value o0.05 considered significant.
RESULTS
Distribution of genotypes and alleles
We genotyped a total of 757 CRC cases for Cys112Arg (rs429358)
and 779 CRC cases for Arg158Cys (rs7412) that give rise to ApoE4
and ApoE2 protein isoforms, respectively. We also genotyped 911
controls for ApoE2 and 864 controls for ApoE4 polymorphisms.
Both polymorphisms are in Hardy–Weinberg equilibrium among
the control population. A typical RFLP HhaI digest is shown in
Supplementary Figure 1. The distribution of ApoE2 and ApoE4
genotypes between all cases and controls as well as cases stratified
by tumour MSI status is shown in Table 1. The frequency of the
ApoE4 allele among the CRC cases and unaffected controls was
13.6 and 14.8%, respectively. The frequency of the ApoE2 allele
among the CRC cases and unaffected controls was 7.0 and 7.6%,
respectively. We did not observe any statistically significant
differences in genotype frequencies between all CRC cases or
CRC subsets and unaffected controls (Table 1).
Analysis of ApoE isoforms and dietary factors in CRC
We observed statistically significant associations of red meat
consumption (Po0.001), total fat intake (Po0.001), saturated fat
intake (P¼0.002), and dietary cholesterol (P¼0.003) with CRC;
however, dietary folacin (P¼0.14) or alcohol intake (P¼0.38) did
not show such association (Table 2). We did not observe any
differences in dietary associations between CRC subsets stratified
by tumour MSI status, except for the inverse association between
drinking more than two alcoholic beverages per week and MSI-H
CRCs (Table 3).
Among ApoE4 variant allele carriers we observed a statistically
significant association between high red meat consumption
(more than four servings per week) and the risk of MSI-H CRCs
when compared with the controls (OR¼4.62, 95% CI 1.20–17.77)
(Table 4A). This association was not observed among non-ApoE4
carriers (Table 4B). However, among non-ApoE4 carriers a
statistically significant association between red meat consumption
(two or more servings of red meat per week) and the risk of MSS/L
CRCs was observed when compared with the controls (for 2–4 red
meat servings per week OR¼1.51, 95% CI 1.10–2.07, and for
more than four red meat servings per week OR¼1.80, 95% CI
1.30–2.48) (Table 4B).
In contrast to ApoE4, we did not observe any statistically
significant associations in ApoE2 carriers between dietary factors
and CRC subsets (Table 5A). Similar to non-ApoE4 carriers, we
observed statistically significant associations among non-ApoE2
carriers of red meat intake, total fat, saturated fat, and cholesterol
intake with the risk of MSS/L and MSI-H CRCs when compared
with the controls (Table 5B).
Among the CRC cases, we observed that MSI-H tumours
occurred more proximally (Po0.001), and were statistically
significantly associated with a higher tumour grade (Po0.001)
when compared with the MSS/L tumours (Supplementary Table).
We did not observe any differences in tumour stage between
MSI-H and MSS/L CRCs.
DISCUSSION
This is the first study, to our knowledge, to examine the
relationship between ApoE isoforms and MSI status in CRC. We
observed that diets rich in fat or red meat increase the risk of CRC
irrespective of tumour MSI status. We did not detect any
differences in dietary folacin or alcohol intake between CRC cases
and controls (Table 2), although it would appear that more than
two alcoholic drinks per week might have a protective effect
against MSI-H CRCs (Table 3). There were no associations between
ApoE genotypes and CRC. When stratified by ApoE4 carrier status,
red meat diet appears to increase the risk of MSI-H CRCs among
ApoE4 carriers and MSS/MSI-L CRCs among non-ApoE4 carriers
Table 1 Distribution of ApoE genotypes by cases and controls
Variable All cases N (%) Controls N (%) P-value OR (95% CI) all cases vs controls
ApoE4
TT 568 (75.0) 634 (73.4) 0.56 1.00 (Referent)
CT 172 (22.7) 204 (23.6) 0.94 (0.75, 1.19)
CC 17 (2.2) 26 (3.0) 0.73 (0.39, 1.36)
ApoE2
TT 673 (86.4) 779 (85.5) 0.69 1.00 (Referent)
CT 103 (13.2) 126 (13.8) 0.95 (0.72, 1.25)
CC 3 (0.4) 6 (0.7) 0.58 (0.14, 2.32)
MSS/L N (%) MSI-H N (%) OR (95% CI) MSS/L vs controls OR (95% CI) MSI-H vs controls
ApoE4
TT 391 (75.0) 63 (73.3) 634 (73.4) 0.85 1.00 (Referent) 1.00 (Referent)
CT 119 (22.8) 20 (23.3) 204 (23.6) 0.95 (0.73, 1.23) 0.99 (0.58, 1.67)
CC 11 (2.1) 3 (3.5) 26 (3.0) 0.69 (0.34, 1.40) 1.16 (0.34, 3.94)
ApoE2
TT 541 (86.8) 94 (84.7) 779 (85.5) 0.70 1.00 (Referent) 1.00 (Referent)
CT/CC 82 (13.2) 17 (15.3) 132 (14.5) 0.89 (0.66, 1.20) 1.07 (0.62, 1.85)
ApoE2 represents ApoE protein with 112Cys/158Cys residues, ApoE4 represents ApoE protein with 112Arg/158Arg residues, MSI-H¼high frequency microsatellite instability,
MSS/L¼microsatellite stable/low-frequency microsatellite instability, homozygous wild-type allele carriers were considered as the referent groups.
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s(Table 4). There is a borderline significant interaction between the
ApoE4 allele, and red meat intake with respect to MSI-H CRCs
(P¼0.06), whereas no significant interaction is detected between
ApoE4 and red meat with respect to MSS CRCs (P¼0.13). Previous
studies on red meat consumption and microsatellite instability
have shown inconsistent results (Palli et al, 2001; Wu et al, 2001;
Diergaarde et al, 2003). Although ApoE4 isoform and fat-rich
diets are a high-risk combination for chronic heart disease and
Alzheimer’s disease, they seem to play a moderate role in the
development of either CRC subtype (Table 4B). Associations with
dietary factors in non-ApoE2 carriers are consistent with our
overall findings (Table 5B). There were no significant associations
among ApoE2 carriers, but the power was low (Table 5A).
The link between red meat intake and CRC has been known for
many years (McKeown-Eyssen and Bright-See, 1984; Norat et al,
2005; Larsson and Wolk, 2006). Red meat contains high levels of
haemoglobin, myoglobin, and cytochromes which are converted
into denatured protein-hemes, hemichromes, and hemochromes,
on cooking (Tappel, 2007). Free and coordinated hemes preferen-
tially catalyse oxidative reactions that can damage DNA, proteins,
lipids, and other nucleic acids (Tappel, 2007). In addition, heme
also damages colonic mucosa and stimulates epithelial prolifera-
tion in animal models (Sesink et al, 1999). Red meat diet also leads
to the formation of hetrocyclic amines and the endogenous
formation of N-nitroso compounds (NOCs) (Cross and Sinha,
2004), which are known potent and organ-specific carcinogens
(Magee and Barnes, 1956; Preussmann, 1984). Rats that were fed
red meat diets showed significantly greater amounts of DNA
single-strand breaks, double-strand breaks, and colonic mucous
layer thinning than rats that were fed white meat diet (Toden et al,
2007).
ApoE has been well established to mediate the cellular uptake of
lipoproteins by binding to the low-density lipoprotein receptor
and the low-density lipoprotein receptor-related protein (LRP)
Table 2 Association of sex, age at diagnosis, red meat intake (servings per week), total fat intake (grams), saturated fat intake (grams), cholesterol intake
(milligrams), dietary folacin (milligrams) and alcohol intake (drinks/week) between CRC cases and controls
Variable Case N (%) Control N (%) Total N (%) P-value OR (95% CI)
Sex
Female 441 (48.7) 402 (46.2) 843 (47.5) 0.30 1.00
Male 465 (51.3) 468 (53.8) 933 (52.5) 0.91 (0.75, 1.09)
Age at diagnosis
o50 113 (12.5) 77 (8.9) 190 (10.7) 0.01 1.00 (Referent)
50–59 257 (28.4) 299 (34.4) 556 (31.3) 0.59 (0.42, 0.82)
60–69 402 (44.4) 372 (42.8) 774 (43.6) 0.74 (0.53, 1.02)
70+ 133 (14.7) 121 (13.9) 254 (14.3) 0.75 (0.51, 1.10)
Red meat consumption/week
0.0–2.0 247 (27.9) 317 (36.8) 564 (32.3) o0.001 1.00 (Referent)
2.1–3.0 186 (21.0) 159 (18.5) 345 (19.7) 1.50 (1.15, 1.97)
3.1–5.0 225 (25.4) 205 (23.8) 430 (24.6) 1.41 (1.09, 1.81)
45.0 228 (25.7) 180 (20.9) 408 (23.4) 1.63 (1.26, 2.10)
Total fat intake (grams)
0–50 175 (19.3) 222 (25.5) 397 (22.4) o0.001 1.00 (Referent)
450–70 262 (28.9) 244 (28.0) 506 (28.5) 1.36 (1.05, 1.77)
470–90 197 (21.7) 205 (23.6) 402 (22.6) 1.22 (0.92, 1.61)
490 272 (30.0) 199 (22.9) 471 (26.5) 1.73 (1.32, 2.27)
Saturated fat intake (grams)
0–15 200 (22.1) 254 (29.2) 454 (25.6) o0.01 1.00 (Referent)
415–20 206 (22.7) 204 (23.4) 410 (23.1) 1.28 (0.98, 1.68)
420–27 234 (25.8) 203 (23.3) 437 (24.6) 1.46 (1.12, 1.91)
427 266 (29.4) 209 (24.0) 475 (26.7) 1.62 (1.25, 2.09)
Dietary cholesterol (milligrams)
0–150 169 (18.7) 216 (24.8) 385 (21.7) o0.01 1.00 (Referent)
4150–220 265 (29.2) 262 (30.1) 527 (29.7) 1.29 (0.99, 1.68)
4220–290 222 (24.5) 202 (23.2) 424 (23.9) 1.40 (1.06, 1.85)
4290 250 (27.6) 190 (21.8) 440 (24.8) 1.68 (1.28, 2.22)
Dietary folacin (miligrams)
0–250 201 (22.2) 214 (24.6) 415 (23.4) 0.14 1.00 (Referent)
4250–370 264 (29.1) 225 (25.9) 489 (27.5) 1.25 (0.96, 1.62)
4370–520 232 (25.6) 203 (23.3) 435 (24.5) 1.22 (0.93, 1.59)
4520 209 (23.1) 228 (26.2) 437 (24.6) 0.98 (0.75, 1.28)
Alcoholic drinks/week
None 224 (25.9) 194 (23.2) 418 (24.6) 0.40 1.00 (Referent)
0.1–2.0 196 (22.6) 208 (24.9) 404 (23.7) 0.82 (0.62, 1.07)
2.1–7.0 228 (26.3) 236 (28.2) 464 (27.3) 0.84 (0.64, 1.09)
47.0 218 (25.2) 198 (23.7) 416 (24.4) 0.95 (0.73, 1.25)
CI¼confidence interval; OR¼odds ratios adjusted for age and sex. All samples with unavailable data have been omitted from the analyses. Female participants, participants with
age o50 along with lowest dietary groups have been used as the referent goups.
ApoE polymorphisms, diet, and CRC
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Female 402 (46.2) 302 (47.2) 71 (63.4) 775 (47.8) o0.01 1.00 (Referent) 1.00 (Referent)
Male 468 (53.8) 338 (52.8) 41 (36.6) 847 (52.2) 0.96 (0.78, 1.18) 0.50 (0.33, 0.75)
Age at diagnosis
o50 77 (8.9) 75 (11.7) 15 (13.4) 167 (10.3) 0.01 1.00 (Referent) 1.00 (Referent)
50–59 299 (34.4) 187 (29.2) 28 (25.0) 514 (31.7) 0.64 (0.44, 0.93) 0.48 (0.24, 0.94)
60–69 372 (42.8) 282 (44.1) 42 (37.5) 696 (42.9) 0.78 (0.55, 1.11) 0.58 (0.31, 1.10)
70+ 121 (13.9) 96 (15.0) 27 (24.1) 244 (15.1) 0.81 (0.54, 1.23) 1.15 (0.57, 2.29)
Red meat consumption/week
0.0–2.0 317 (36.8) 170 (27.2) 30 (27.3) 517 (32.4) o0.01 1.00 (Referent) 1.00 (Referent)
2.1–3.0 159 (18.5) 134 (21.5) 25 (22.7) 318 (19.9) 1.57 (1.17, 2.11) 1.66 (0.95, 2.92)
3.1–5.0 205 (23.8) 162 (26.0) 29 (26.4) 396 (24.8) 1.47 (1.12, 1.95) 1.49 (0.87, 2.56)
45.0 180 (20.9) 158 (25.3) 26 (23.6) 364 (22.8) 1.64 (1.23, 2.17) 1.53 (0.88, 2.66)
Red meat consumption/week (tertiles)
0.0–2.0 317 (36.8) 170 (27.2) 30 (27.3) 517 (32.4) o0.001 1.00 (Referent) 1.00 (Referent)
2.1–4.0 293 (34.0) 227 (36.4) 49 (44.5) 569 (35.7) 1.44 (1.12, 1.86) 1.77 (1.09, 2.86)
44.0 251 (29.2) 227 (36.4) 31 (28.2) 509 (31.9) 1.69 (1.30, 2.18) 1.31 (0.77, 2.21)
Total fat intake
0–50 222 (25.5) 122 (19.1) 20 (17.9) 364 (22.4) 0.01 1.00 (Referent) 1.00 (Referent)
450–70 244 (28.0) 189 (29.5) 30 (26.8) 463 (28.5) 1.41 (1.05, 1.89) 1.36 (0.75, 2.47)
470–90 205 (23.6) 140 (21.9) 27 (24.1) 372 (22.9) 1.24 (0.91, 1.69) 1.46 (0.80, 2.69)
490 199 (22.9) 189 (29.5) 35 (31.3) 423 (26.1) 1.73 (1.28, 2.33) 1.95 (1.09, 3.49)
Total fat intake (tertiles)
0–57 315 (36.2) 183 (28.6) 31 (27.7) 529 (32.6) o0.01 1.00 (Referent) 1.00 (Referent)
457–83 300 (34.5) 226 (35.3) 37 (35.3) 563 (34.7) 1.30 (1.01, 1.67) 1.25 (0.76, 2.07)
483 255 (29.3) 231 (36.1) 44 (39.3) 530 (32.7) 1.56 (1.21, 2.01) 1.75 (1.08, 2.86)
Saturated fat intake
0–15 254 (29.2) 140 (21.9) 22 (19.6) 416 (25.6) o0.01 1.00 (Referent) 1.00 (Referent)
415–20 204 (23.4) 149 (23.3) 21 (18.8) 374 (23.1) 1.33 (0.99, 1.78) 1.19 (0.64, 2.22)
420–27 203 (23.3) 166 (25.9) 35 (31.3) 404 (24.9) 1.48 (1.11, 1.98) 1.99 (1.13, 3.50)
427 209 (24.0) 185 (28.9) 34 (30.4) 428 (26.4) 1.61 (1.21, 2.14) 1.88 (1.07, 3.31)
Saturated fat intake (tertiles)
0–18 384 (44.1) 223 (34.8) 36 (32.1) 643 (39.6) o0.001 1.00 (Referent) 1.00 (Referent)
418–25 230 (26.4) 197 (30.8) 29 (25.9) 456 (28.1) 1.47 (1.15, 1.90) 1.34 (0.80, 2.25)
425 256 (29.4) 220 (34.4) 47 (42.0) 523 (32.2) 1.48 (1.16, 1.89) 1.96 (1.23, 3.11)
Dietary cholesterol
0–150 216 (24.8) 114 (17.8) 24 (21.4) 354 (21.8) 0.02 1.00 (Referent) 1.00 (Referent)
4150–220 262 (30.1) 187 (29.2) 30 (26.8) 479 (29.5) 1.35 (1.01, 1.82) 1.03 (0.58, 1.82)
4220–290 202 (23.2) 168 (26.3) 25 (22.3) 395 (24.4) 1.58 (1.16, 2.14) 1.11 (0.62, 2.01)
4290 190 (21.8) 171 (26.7) 33 (29.5) 394 (24.3) 1.71 (1.25, 2.32) 1.56 (0.89, 2.74)
Dietary cholesterol (tertiles)
0–180 334 (38.4) 190 (29.7) 42 (37.5) 566 (34.9) o0.01 1.00 (Referent) 1.00 (Referent)
4180–260 267 (30.7) 219 (34.2) 29 (25.9) 515 (31.8) 1.44 (1.12, 1.86) 0.86 (0.52, 1.42)
4260 269 (30.9) 231 (36.1) 41 (36.6) 541 (33.4) 1.51 (1.18, 1.94) 1.21 (0.77, 1.92)
Dietary folacin
0–250 214 (24.6) 137 (21.4) 24 (21.4) 375 (23.1) 0.34 1.00 (Referent) 1.00 (Referent)
4250–370 225 (25.9) 192 (30.0) 32 (28.6) 449 (27.7) 1.33 (1.00, 1.78) 1.27 (0.72, 2.22)
4370–520 203 (23.3) 165 (25.8) 27 (24.1) 395 (24.4) 1.27 (0.94, 1.71) 1.19 (0.66, 2.12)
4520 228 (26.2) 146 (22.8) 29 (25.9) 403 (24.8) 1.00 (0.74, 1.35) 1.13 (0.64, 2.01)
Dietary folacin (tertiles)
0–290 299 (34.4) 202 (31.6) 38 (33.9) 539 (33.2) 0.37 1.00 (Referent) 1.00 (Referent)
4290–460 277 (31.8) 235 (36.7) 35 (31.3) 547 (33.7) 1.26 (0.98, 1.61) 0.99 (0.61, 1.62)
4460 294 (33.8) 203 (31.7) 39 (34.8) 536 (33.0) 1.02 (0.79, 1.32) 1.04 (0.65, 1.68)
Alcoholic drinks/week
None 194 (23.2) 146 (23.9) 39 (36.1) 379 (24.4) 0.11 1.00 (Referent) 1.00 (Referent)
0.1–2.0 208 (24.9) 140 (22.9) 25 (23.1) 373 (24.0) 0.89 (0.66, 1.21) 0.60 (0.35, 1.02)
2.1–7.0 236 (28.2) 171 (28.0) 23 (21.3) 430 (27.7) 0.96 (0.72, 1.29) 0.48 (0.28, 0.84)
47.0 198 (23.7) 154 (25.2) 21 (19.4) 373 (24.0) 1.03 (0.77, 1.40) 0.53 (0.30, 0.93)
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s(Lund et al, 1989; Yamada et al, 1992). However, ApoE also
performs other crucial functions, and aberration of these functions
may lead to cancer (Vogel et al, 1994; Grocott et al, 2001; Niemi
et al, 2002; Cedazo-Minguez et al, 2003). ApoE binds heparin and
proteoglycans with very high affinity and inhibits proliferation of
several cell types such as: endothelial cells, lymphocytes, smooth
muscle cells, and several types of tumour cells (Cardin et al, 1988;
Ji et al, 1993; Browning et al, 1994; Vogel et al, 1994; Ishigami et al,
1998). In vitro studies suggest that treatment of colon cancer cell
line HT29 with ApoE enhanced cell polarity by translocating
b-catenin from the cytoplasm to cell–cell adhesion sites (Niemi
et al, 2002). ApoE is a potent inhibitor of cell proliferation and
de novo DNA synthesis (Vogel et al, 1994). Functional studies on
ApoE isoforms showed that ApoE4, but not wild-type ApoE,
significantly inhibits GSK-3b and increases the amount of active
PKB (which further inactivates GSK-3b), leading to enhanced
b-catenin translocation into the nucleus (Cedazo-Minguez et al,
2003). Nuclear b-catenin promotes transcription of genes involved
in cell survival and division (Behrens et al, 1996; Molenaar et al,
1996; Pap and Cooper, 1998). These results would indicate that
ApoE4 has pro-proliferative and anti-apoptotic properties.
Taken together, we propose that the selective effects of red meat
diet on MSI-H CRC in ApoE4 carriers may be due to the anti-
apoptotic and pro-proliferative effects of ApoE4. Heme and NOCs
from red meat diets cause oxidative damage and DNA adduct
formation, but rather than initiating cell cycle arrest and DNA
repair, ApoE4-expressing cells induce pro-survival and prolifera-
tive signals. This would place a substantial strain on DNA repair
machinery until a certain threshold level is reached beyond which
the DNA repair mechanism is ineffective and genomic stability
is compromised. Such cells would not undergo apoptosis even
when extensive DNA damage is present. In addition, ApoE4 has
poor antioxidant properties, compared with ApoE2, and combined
with its proinflammatory functions may further exacerbate the
tumourigenic process (Miyata and Smith, 1996; Jofre-Monseny
et al, 2007). Conversely, ApoE2 and wild-type ApoE carriers would
be able to better modulate aberrant cellular proliferation, inhibit
oxidating and proinflammatory agents, allowing DNA repair
machinery to more effectively repair DNA damage. Studies
including fruits, vegetables, and antioxidant nutrients and their
interaction with ApoE isoforms will further clarify this possible
mechanism.
The main strength of our study is a well-characterised
population. The frequencies of ApoE genotypes in our population
are very similar to those of reports published earlier (Watson et al,
2003; Slattery et al, 2005; Bennet et al, 2007). We observed a strong
association of MSI-H CRCs with female patients (Table 3),
proximal colon location and higher tumour grades (Supplemen-
tary Table) consistent with reports published earlier (Thibodeau
et al, 1993; Gryfe et al, 2000; Samowitz et al, 2001; Ribic et al,
2003). Limitations of our study are the small sample size of MSI-H
CRCs and the low frequency of the ApoE2 polymorphism, which
reduces our power to observe significant interactions among ApoE
genotypes and dietary variables. Although the findings presented
in this study need to be independently validated in another
population, further characterisation of ApoE polymorphisms and
Table 4 Association of dietary factors between CRC cases stratified by MSI tumour status and controls by ApoE4 allele carrier status
Variable Controls N (%) MSS/L N (%) MSI-H N (%) OR (95% CI) MSS/L vs controls OR (95% CI) MSI-H vs controls
(A) ApoE4 carriers
Red meat consumption/week
0.0–2.0 81 (35.8) 42 (33.3) 3 (13.6) 1.00 (Referent) 1.00 (Referent)
2.1–4.0 78 (34.5) 45 (35.7) 9 (40.9) 1.13 (0.67, 1.91) 3.25 (0.84, 12.56)
44.0 67 (29.7) 39 (31.0) 10 (45.5) 1.16 (0.67, 2.02) 4.62 (1.20, 17.77)
Dietary cholesterol (milligrams)
0–180 89 (38.7) 42 (32.3) 9 (39.1) 1.00 (Referent) 1.00 (Referent)
4180–260 72 (31.3) 38 (29.2) 7 (30.4) 1.24 (0.71, 2.15) 1.11 (0.38, 3.18)
4260 69 (30.0) 50 (38.5) 7 (30.4) 1.87 (1.08, 3.26) 1.22 (0.41, 3.69)
Saturated fat intake (grams)
0–18 104 (45.2) 52 (40.0) 8 (34.8) 1.00 (Referent) 1.00 (Referent)
418–25 58 (25.2) 37 (28.5) 5 (21.7) 1.37 (0.80, 2.34) 1.22 (0.38, 3.96)
425 68 (29.6) 41 (31.5) 10 (43.5) 1.36 (0.80, 2.32) 2.31 (0.83, 6.40)
Total fat intake (grams)
0–57 82 (35.6) 39 (30.0) 5 (21.7) 1.00 (Referent) 1.00 (Referent)
457–83 83 (36.1) 50 (38.5) 9 (39.1) 1.37 (0.81, 2.32) 2.01 (0.64, 6.36)
483 65 (28.3) 41 (31.5) 9 (39.1) 1.58 (0.89, 2.81) 3.01 (0.91, 9.95)
(B) Non-ApoE4 carriers
Red meat consumption/week
0.0–2.0 234 (37.2) 101 (26.5) 21 (33.9) 1.00 (Referent) 1.00 (Referent)
2.1–4.0 215 (34.2) 140 (36.8) 25 (40.3) 1.51 (1.10, 2.07) 1.33 (0.72, 2.46)
44.0 180 (28.6) 140 (36.8) 16 (25.8) 1.80 (1.30, 2.48) 1.03 (0.52, 2.05)
Dietary cholesterol (milligrams)
0–180 242 (38.2) 109 (27.9) 25 (39.7) 1.00 (Referent) 1.00 (Referent)
4180–260 194 (30.6) 142 (36.3) 14 (22.2) 1.64 (1.20, 2.25) 0.81 (0.41, 1.62)
4260 198 (31.2) 140 (35.8) 24 (38.1) 1.58 (1.14, 2.18) 1.58 (0.85, 2.93)
Saturated fat intake (grams)
0–18 277 (43.7) 128 (32.7) 20 (31.8) 1.00 (Referent) 1.00 (Referent)
418–25 171 (27.0) 125 (32.0) 15 (23.8) 1.60 (1.17, 2.19) 1.38 (0.68, 2.80)
425 186 (29.3) 138 (35.3) 28 (44.4) 1.61 (1.18, 2.20) 2.80 (1.50, 5.25)
Total fat intake (grams)
0–57 230 (36.3) 108 (27.6) 19 (30.2) 1.00 (Referent) 1.00 (Referent)
457–83 216 (34.1) 134 (34.3) 18 (28.6) 1.34 (0.98, 1.84) 1.14 (0.58, 2.26)
483 188 (29.6) 149 (38.1) 26 (41.3) 1.71 (1.24, 2.37) 2.29 (1.20, 4.38)
CI¼confidence interval; MSI-H¼high frequency microsatellite instability; MSS/L¼microsatellite stable/low-frequency microsatellite instability; OR¼odds ratios adjusted for age
and sex. All samples with unavailable data have been omitted from the analyses. Lowest dietary groups have been used as the referent groups.
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sdietary or environmental factors, may provide new insights into
the gene–diet and gene–environment interactions and their
contribution to incidence and progression of colon cancer or its
subtypes.
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